1. Bollerslev J, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug;173(2):G1-20.
  2. Brandi ML, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2016 Jun 1;101(6):2273–83.
  3. Chen K, et al. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. Journal of Medical Economics. 2019 Jun 17;22(11):1141–52.
  4. Mannstadt M, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017 Aug 31;3:17055.
  5. Clarke BL, et al. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016 Jun 1;101(6):2284–2299.
  6. Khan AA, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019 Mar 01;180(3):1-22.
  7. Ascendis Pharma UK. Data on file. 2025.
  8. Shoback DM, et al. J Clin Endocrinol Metab. 2016;101(6):2300–12.
  9. National Cancer Institute. Bone Density. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bone-density. [accessed October 2025].
  10. Medline Plus. Calcification. Available from: https://medlineplus.gov/ency/article/002321.htm [accessed October 2025].
  11. National Cancer Institute. Cognitive impairment. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cognitive-impairment. [accessed October 2025].
  12. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
  13. Qadeer HA, Bashire K. Physiology, Phosphate. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560925/. [accessed October 2025].
  14. Goyal A, et al. Hypocalcemia. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430912/. [accessed October 2025].
  15. Goyal R, Jialal I. Hyperphosphatemia. StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551586/. [accessed October 2025].
  16. National Cancer Institute. Renal Failure. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/renal-failure. [accessed October 2025].
  17. Brod M, et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Qual Life Res. 2021 Jan;30(1):277-291. doi: 10.1007/s11136-020-02607-1. Epub 2020 Aug 24. PMID: 32833143; PMCID: PMC7847873.
  18. Kontogeorgos G, et al. Low health-related quality of life in hypoparathyroidism and need for PTH analog. Endocrine Connections. 2022 Jan 10;11(1).
  19. Ascendis Pharma UK. Data on file. 2024.

Expert Views on Hypopara

Woman with coffee looking out of a window

Expert Views on Hypopara

The Seeds of Change initiative is committed to supporting greater understanding of hypoparathyroidism (hypopara) and the impact it has on patients’ lives. Through collaboration with leading professionals in hypopara, we explore the complexities of hypopara management, share insights from real patient experiences, and reflect on how clinical practice can continue to evolve – helping healthcare professionals better support those living with this rare condition.

Articles

Beyond the Numbers: Breaking Down Misconceptions in Hypoparathyroidism

Dr Hassan-Smith reflects on the potential limitations of a metrics-only approach to hypopara management, the need to recognise psychological burden, long-term complications, and the role of patient empowerment and community support in improving outcomes.

Download
Dr Zaki Hassan Smith

By Dr Zaki Hassan-Smith, Honorary Consultant Endocrinologist, University Hospitals Birmingham NHS Foundation Trust; Clinical Associate Professor, Aston University.

The Silent Condition: Managing Long-Term Complications in Hypoparathyroidism

Dr Abbas focuses on the often-overlooked long-term complications of hypopara, including renal, cardiovascular, bone and cognitive risk.

He highlights the importance of proactive monitoring, multidisciplinary care and patient education to achieve improved long-term outcomes for people living with hypopara.

Download
Dr Afroze Abbas

By Dr Afroze Abbas, Consultant Endocrinologist, Leeds Teaching Hospitals NHS Trust.

Missing from the Metrics: Navigating Symptom Fluctuations in Hypopara Care for Women

Dr Victoria Stokes discusses the challenges faced by women living with hypoparathyroidism, particularly during pregnancy, postpartum, and perimenopause, where hormonal fluctuations and life stages complicate symptom management and monitoring. She highlights the potential limitations of current care models that rely on infrequent biochemical assessments, advocating for more dynamic, patient-centred approaches.

Download
Victoria Stokes

By Dr Victoria Stokes, Consultant Endocrinologist at Cambridge University Hospitals NHS Foundation Trust.

Think Calcium, Think Long-Term: Bridging the Gaps in the Hypoparathyroidism Care Pathway

Professor Selby Professor Selby provides advice on identifying and addressing gaps in the hypopara patient pathway, and the importance of primary and secondary care professionals remaining vigilant to calcium monitoring and the risk of long-term consequences.

Download
Professor Peter Selby

By Professor Peter Selby, Consultant Physician and Honorary Clinical Professor of Metabolic Bone Disease.

“For some people with hypopara, their symptoms can be well managed. For others however, managing the condition can be very challenging, mainly due to its broad and indistinct symptoms”

Dr Zaki Hassan-Smith

“Clinicians must remain vigilant about the potential long-term complications of hypopara that can emerge over time”

Dr Zaki Hassan-Smith

“Evolving management practices that include comprehensive long-term care strategies are required to ensure physicians can keep patients out of hospital, whilst minimising the complications related to chronic hypopara”

Dr Zaki Hassan-Smith

“In today’s hypopara treatment landscape, the current focus on short-term serum calcium correction is not going far enough. Effective management demands a broader and more comprehensive approach”

Dr Afroze Abbas

“Looking ahead, we must reframe the way we think about hypopara. This includes investment in and implementing more regular proactive surveillance of long-term complications”

Dr Afroze Abbas

“We must continue focusing on patient education and empowerment, to help individuals living with hypopara and their families to better understand their condition and manage symptoms”

Dr Afroze Abbas

“To ensure continuity of care, it is critical that all healthcare professionals involved in maternity care, including obstetricians, midwives and general practitioners, are aware of the continuous monitoring requirements for women with hypopara”

Dr Victoria Stokes

“Differentiating between perimenopausal changes and hypopara-related symptom manifestations can be challenging for both patients and clinicians. This often necessitates a more nuanced and collaborative approach to management”

Dr Victoria Stokes

“Optimising the hypopara pathway requires a multi-pronged approach across primary care professionals (from GPs to pharmacists), endocrinologists (specialist bone and calcium experts and more general endocrine doctors and nurses), and patients and carers themselves”

Professor Peter Selby

“We need to improve the systematic review of long-term medication use to ensure that proactive monitoring is embedded and therefore over-treatment is flagged early. Other chronic conditions, like diabetes, offer a useful comparison”

Professor Peter Selby